Wharton’s Jelly-Derived Mesenchymal Stem Cell Transplantation in a Patient with Hypoxic-Ischemic Encephalopathy A Pilot Study

• Published in: Cell transplantation Vol. 27; no. 10; pp. 1425 - 1433
• Main Authors: Kabataş, Serdar, Civelek, Erdinç, İnci, Çiğdem, Yalçınkaya, Ebru Yılmaz, Günel, Gülşen, Kır, Gülay, Albayrak, Esra, Öztürk, Erek, Adaş, Gökhan, Karaöz, Erdal
• Format: Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01-10-2018
• Subjects: Original; wharton’s jelly; hypoxic-ischemic encephalopathy; stem cell therapy; post-cardiopulmonary resuscitation
• ISSN: 0963-6897; 1555-3892
• DOI: 10.1177/0963689718786692

Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) have been introduced as a possible therapy in hypoxic-ischemic encephalopathy (HIE). We report a 16-year-old boy who was treated with WJ-MSCs in the course of HIE due to post-cardiopulmonary resuscitation. He received a long period of mechanical ventilation and tracheostomy with spastic quadriparesis. He underwent the intrathecal (1×106/kg in 3 mL), intramuscular (1×106/kg in 20 mL) and intravenous (1×106/kg in 30 mL) administrations of WJ-MSCs for each application route (twice a month for 2 months). After stem cell infusions, progressive improvements were shown in his neurological examination, neuroradiological, and neurophysiological findings. To our best knowledge, this is a pioneer project to clinically study the neural repair effect of WJ-MSCs in a patient with HIE.